

RECEIVED
CENTRAL FAX CENTER

NOV 29 2006

Atty. Docket No. 1311-CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/623,189

Inventors: Alex De Paoli, et al.

Filed: July 18, 2003

Title: USE OF LEPTIN FOR TREATING HUMAN
LIPOATROPHY AND METHOD OF DETERMINING
PREDISPOSITION TO SAID TREATMENT


Confirmation No.: 3581

TC/A.U.: 1646

Examiner: O'Hara, Eileen B.

FACSIMILE TRANSMITTAL COVER SHEETCertificate of Transmission Under 37 C.F.R. 1.8

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number (571) 273-8300 on this 29th day of November, 2006.



Rachel Potash

Document(s)

1. Issue Fee Transmittal (PTOL-85) [in duplicate];
2. Comments on Statement for Reasons for Allowance

No. of Pages

- 1 page + duplicate.
2 pages

Total number of pages transmitted (including this page):

5

*NOTE: Each paper must have its own certificate of transmission,
or this certificate must identify each paper submitted*

NOV 29 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/623,189

Inventors: Alex De Paoli, et al.

Filed: July 18, 2003

Title: USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY
AND METHOD OF DETERMINING PREDISPOSITION TO SAID
TREATMENT

Confirmation No.: 3581

TC/A.U.: 1646

Examiner: O'Hara, Eileen B.

COMMENTS ON STATEMENT FOR REASONS FOR ALLOWANCE

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

Applicant would like to thank the Examiner for her helpful comments in the telephone interview dated July 5, 2006, which comments are reiterated in the Examiner's Amendment and Statement of Reasons for Allowance that accompanied the Notice of Allowance that issued in the instant application. In particular, Applicant thanks the Examiner for acknowledging that the allowed claims are novel, non-obvious, and fully enabled in light of the prior art.

Additionally, Applicant respectfully calls to the Examiner's attention an apparent typographical error in the Notice of Allowability that issued in the instant application, in which Claims 1-22 and 23-31 are listed as the allowed claims. Claim 22 was previously withdrawn, without prejudice, as being directed to non-elected subject matter, and is presented in independent form for prosecution in a divisional application, filed on November 29, 2006. Therefore, the allowed claims in the instant case are Claims 1-21 and 23-31.


Comments on Statement on Reasons for Allowance

Atty. Docket No. 1311-CON

It is believed that no fees are due in connection with these Comments. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535, referencing matter number 1311US-CON. Additionally, the Commissioner is hereby authorized to charge any underpayment or credit overpayment of fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: November 29, 2006

By: 
Michael D. Ruse, Jr.
Registration No. 55,900

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936